Inactive Instrument

Highlights PDL BioPharma, Inc.

Equities

PDLI

US69329Y1047

Highlights

Unlock all the news: Be the first to know and act before the market!

PDL BioPharma, Inc.'s Equity Buyback announced on December 9, 2019 has expired with the repurchase of 15,532,000 shares, representing 12.91% for $50.39 million.	21-12-30	CI
Tranche Update on PDL BioPharma, Inc.'s Equity Buyback Plan announced on December 9, 2019.	21-03-29	CI
PDL BioPharma, Inc. Announces Unaudited Consolidated Earnings Results for the Two Months and Eight Months Ended August 31, 2020	20-11-11	CI
Tranche Update on PDL BioPharma, Inc.'s Equity Buyback Plan announced on December 9, 2019.	20-11-10	CI
Spin off	20-10-01	FA
PDL BioPharma, Inc. completed the Spin-Off of LENSAR, Inc..	20-09-30	CI
PDL BioPharma, Inc. Provides Revenue Guidance for 2022	20-09-10	CI
Stanley Capital completed the acquisition of Noden Pharma DAC and Noden Pharma USA, Inc. from PDL BioPharma, Inc. for $52.8 million.	20-09-08	CI
Tranche Update on PDL BioPharma, Inc.'s Equity Buyback Plan announced on December 9, 2019.	20-08-06	CI
Pdl Biopharma, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-06	CI
Stanley Capital Limited entered into a definitive agreement to acquire Noden Pharma DAC and Noden Pharma USA, Inc. from PDL BioPharma, Inc. for $48.3 million.	20-07-29	CI
The management Board of PDL BioPharma, Inc. announced the spin off of its stake in LENSAR, Inc.	20-07-16	CI
PDL BioPharma, Inc. completed the spin-off 26.8% stake in Evofem Biosciences, Inc. for $67 million.	20-05-20	CI
Spin off	20-05-13	FA
Tranche Update on PDL BioPharma, Inc.'s Equity Buyback Plan announced on December 9, 2019.	20-05-07	CI
Pdl Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-07	CI
Pdl Biopharma Declares Dividend of Evofem Biosciences Common Stock to PDL Stockholders, Payable on May 21, 2020	20-05-05	CI
PDL BioPharma, Inc. announced the spin-off 26.8% stake in Evofem Biosciences, Inc. for $70.4 million.	20-05-04	CI
Tranche Update on PDL BioPharma, Inc.'s Equity Buyback Plan announced on December 9, 2019.	20-03-11	CI
Pdl Biopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	20-03-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PDL BioPharma, Inc.

Equities

PDLI

US69329Y1047

Highlights

Filters